Circassia Pharmaceuticals PLC | Mutual Funds
Mutual Funds that own Circassia Pharmaceuticals PLC
CF Woodford Equity Income
57,625,647
16.13%
0
0.72%
07/31/2018
Invesco Perpetual UK Invt. Ser. - High Income
47,728,135
13.36%
-3,542,060
0.38%
03/29/2018
Invesco Perpetual UK 2 Invt. Series - Income Fund
28,261,948
7.91%
-2,198,329
0.47%
03/29/2018
Neptune Investment Funds - UK Mid Cap Fund
18,355,163
5.14%
7,229,411
3.06%
06/30/2017
Oppenheimer Global Fund
17,318,782
4.84%
0
0.14%
03/31/2018
St. James's Place Unit Trust - UK High Income
5,318,106
1.49%
0
0.23%
03/31/2018
Edinburgh Investment Trust Plc
5,020,560
1.41%
-345,526
0.23%
03/31/2018
Oppenheimer Variable - Global Fund
4,471,614
1.25%
0
0.16%
03/31/2018
Perpetual Income & Growth Investment Trust Plc
4,337,153
1.21%
-327,553
0.3%
03/31/2018
JNL/Oppenheimer Global Growth Series
3,352,516
0.94%
0
0.12%
03/31/2018
| Address |
Northbrook House
Oxford Oxfordshire OX4 4GA
United Kingdom
|
|
Employees
|
- |
| Website |
http://circassia.com |
| Updated |
07/08/2019 |
| Circassia Pharmaceuticals Plc is a biopharmaceutical company, which engages in the development and commercialization of allergy, asthma, and respiratory products. It operates through the following segments: NIOX, Respiratory, and US AZ Collaboration. The NIOX segment provides a portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide. |
